JRCT ID: jRCT2031230093
Registered date:26/05/2023
Post-marketing Surveillance Protocol Number; CAAA601A11401
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Somatostatin receptor-positive neuroendocrine tumor |
Date of first enrollment | 16/12/2021 |
Target sample size | 300 |
Countries of recruitment | |
Study type | Observational |
Intervention(s) |
Outcome(s)
Primary Outcome | Numbers of patients and incidence proportions of Renal dysfunction, Myelosuppression, Myelodysplastic syndrome/acute myeloid leukaemia and Hormone release induced crises |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | Not applicable |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | All patients treated with asciminib |
Exclude criteria | N/A |
Related Information
Primary Sponsor | Toshiya Sugimoto |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Novartis Direct |
Address | Toranomon Hills Mori Tower 23-1, Toranomon 1-chome Minato-ku, Tokyo 105-6333, Japan Tokyo Japan 105-6333 |
Telephone | +81-120-003-293 |
sm.pms@novartis.com | |
Affiliation | Novartis Pharma. K.K. |
Scientific contact | |
Name | Sugimoto Toshiya |
Address | Toranomon Hills Mori Tower 23-1, Toranomon 1-chome Minato-ku, Tokyo 105-6333, Japan Tokyo Japan 105-6333 |
Telephone | +81-120-003-293 |
sm.pms@novartis.com | |
Affiliation | Novartis Pharma. K.K. |